LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.

Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.

Infarction, Anterior Cerebral Artery

Infarction, Middle Cerebral Artery

Ischemic Attack, Transient

Bach Mai Hospital

Phu Tho General Hospital

103 Military Hospital

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

A Non-interventional, Controlled, Open-label, Observational Registry Study to Investigate the Safety and Effectiveness of LUOTAI (Panax Notoginseng) Injectable and Soft Capsules in Patients With Acute Ischemic Stroke in Vietnam

Modified Rankin Scale (mRS) is an overall functional outcome measure, measuring stroke defect. Answer the test questions for 5-10 minutes. The score range is 7 points with a score of 0 for the absence of sequelae and the worst possible score is 6.
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead. Primary Efficacy Endpoint defined as "Categorical shift in mRS score at 3 months (ordinal logistic regression analysis of the mRS on Day 90)".

Ordinal NIHSS at 3 months after stroke onset

Ordinal MoCA at 3 months after stroke onset

Proportion of patients with excellent recovery and functional dependence at 3 months after stroke onset (mRC=0 or 1)

KPC Pharmaceuticals, Inc

Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.

Hyperlipidemias

Hypertension

A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.

Farlong NotoGinseng™ (Farlong Ginseng Plus®)

Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg

Placebo

The Effect of Farlong® NotoGinseng™ (Farlong® Ginseng Plu®) on Cholesterol and Blood Pressure

A Randomized, Placebo-controlled, Double-blind, Parallel Study to Determine the Effect of Farlong® NotoGinseng™ (Farlong® Ginseng Plu®) on Cholesterol and Blood Pressure

The difference in serum LDL-C from baseline to week 12 between Farlong NotoGinseng™ (Farlong Ginseng Plus®) and placebo after 12 weeks of supplementation.

1. The difference in serum LDL-C from baseline to week 8 between Farlong Notoginseng and placebo

2. The difference in blood pressure from baseline to week 8 between Farlong Notoginseng and placebo

3. The difference in blood pressure from baseline to week 12 between Farlong Notoginseng and placebo

4. The difference in triglycerides from baseline to week 8 between Farlong Notoginseng and placebo

5. The difference in triglycerides from baseline to week 12 between Farlong Notoginseng and placebo

6. The difference in HDL-C from baseline to week 8 between Farlong Notoginseng and placebo

7. The difference in HDL-C from baseline to week 12 between Farlong Notoginseng and placebo

8. The difference in total cholesterol from baseline to week 8 between Farlong Notoginseng and placebo

9. The difference in total cholesterol from baseline to week 12 between Farlong Notoginseng and placebo

10. The difference in endothelial vasodilation, as measured by the EndoPAT, from baseline to week 8 between Farlong Notoginseng and placebo

11. The difference in endothelial vasodilation, as measured by the EndoPAT, from baseline to week 12 between Farlong Notoginseng and placebo

LongStar HealthPro, Inc. DBA Farlong Pharmaceutical

Yunnan PanLongYunHai Pharmaceuticals, Ltd.

KGK Science Inc.

This was a randomized, placebo-controlled, double-blind, parallel study with a 4-week therapeutic lifestyle change diet (TLC) run-in period and a 12-week supplementation period.

notoginsenoside/panax notoginseng

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

The Effect of Farlong® NotoGinseng™ (Farlong® Ginseng Plu®) on Cholesterol and Blood Pressure

Baz done ki pi konplè remèd fèy medsin te apiye nan syans